Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Income (2016 - 2025)

Arrowhead Pharmaceuticals' Operating Income history spans 16 years, with the latest figure at $40.8 million for Q4 2025.

  • For Q4 2025, Operating Income rose 125.28% year-over-year to $40.8 million; the TTM value through Dec 2025 reached $300.6 million, up 148.02%, while the annual FY2025 figure was $98.3 million, 116.36% up from the prior year.
  • Operating Income reached $40.8 million in Q4 2025 per ARWR's latest filing, down from $44.1 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $381.2 million in Q1 2025 to a low of -$176.1 million in Q2 2024.
  • Average Operating Income over 5 years is -$48.5 million, with a median of -$68.9 million recorded in 2021.
  • Peak YoY movement for Operating Income: crashed 362.0% in 2024, then skyrocketed 402.08% in 2025.
  • A 5-year view of Operating Income shows it stood at -$63.3 million in 2021, then soared by 33.46% to -$42.1 million in 2022, then crashed by 224.07% to -$136.5 million in 2023, then decreased by 18.21% to -$161.4 million in 2024, then soared by 125.28% to $40.8 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Operating Income are $40.8 million (Q4 2025), $44.1 million (Q3 2025), and -$165.5 million (Q2 2025).